1034 related articles for article (PubMed ID: 18559698)
41. Left ventricular function after ST-elevation myocardial infarction in patients treated with primary percutaneous coronary intervention and abciximab or tirofiban (from the Facilitated Angioplasty with Tirofiban or Abciximab [FATA] Trial).
Taglieri N; Saia F; Guiducci V; Tondi S; Conrotto F; Marrozzini C; Rocchi G; Biagini E; Reggiani ML; Giacometti P; Piovaccari G; Manari A; Marzocchi A;
Am J Cardiol; 2009 Mar; 103(6):785-90. PubMed ID: 19268732
[TBL] [Abstract][Full Text] [Related]
42. Relation between white blood cell count and final infarct size in patients with ST-segment elevation acute myocardial infarction undergoing primary percutaneous coronary intervention (from the INFUSE AMI trial).
Palmerini T; Brener SJ; Genereux P; Maehara A; Della Riva D; Mariani A; Witzenbichler B; Godlewski J; Parise H; Dambrink JH; Ochala A; Fahy M; Xu K; Gibson CM; Stone GW
Am J Cardiol; 2013 Dec; 112(12):1860-6. PubMed ID: 24063843
[TBL] [Abstract][Full Text] [Related]
43. Persistent coronary no flow after wire insertion is an early and readily available mortality risk factor despite successful mechanical intervention in acute myocardial infarction: a pooled analysis from the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials.
Valgimigli M; Campo G; Malagutti P; Anselmi M; Bolognese L; Ribichini F; Boccuzzi G; de Cesare N; Rodriguez AE; Russo F; Moreno R; Biondi-Zoccai G; Penzo C; Díaz Fernández JF; Parrinello G; Ferrari R
JACC Cardiovasc Interv; 2011 Jan; 4(1):51-62. PubMed ID: 21251629
[TBL] [Abstract][Full Text] [Related]
44. Effect of high-dose intracoronary adenosine administration during primary percutaneous coronary intervention in acute myocardial infarction: a randomized controlled trial.
Fokkema ML; Vlaar PJ; Vogelzang M; Gu YL; Kampinga MA; de Smet BJ; Jessurun GA; Anthonio RL; van den Heuvel AF; Tan ES; Zijlstra F
Circ Cardiovasc Interv; 2009 Aug; 2(4):323-9. PubMed ID: 20031735
[TBL] [Abstract][Full Text] [Related]
45. Beneficial effects of intracoronary tirofiban bolus administration following upstream intravenous treatment in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the ICT-AMI study.
Zhu TQ; Zhang Q; Qiu JP; Jin HG; Lu L; Shen J; Zhao LP; Zhang RY; Hu J; Yang ZK; Shen WF
Int J Cardiol; 2013 May; 165(3):437-43. PubMed ID: 21940058
[TBL] [Abstract][Full Text] [Related]
46. Prehospital versus periprocedural abciximab in ST-elevation myocardial infarction treated by percutaneous coronary intervention.
Pels K; Schröder J; Witzenbichler B; Müller D; Morguet A; Pauschinger M; Schultheiss HP; Arntz HR
Eur J Emerg Med; 2008 Dec; 15(6):324-9. PubMed ID: 19078834
[TBL] [Abstract][Full Text] [Related]
47. Platelet inhibition and GP IIb/IIIa receptor occupancy by intracoronary versus intravenous bolus administration of abciximab in patients with ST-elevation myocardial infarction.
Desch S; Siegemund A; Scholz U; Adam N; Eitel I; de Waha S; Fürnau G; Lurz P; Wetzel S; Schuler G; Thiele H
Clin Res Cardiol; 2012 Feb; 101(2):117-24. PubMed ID: 22015616
[TBL] [Abstract][Full Text] [Related]
48. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.
Valgimigli M; Campo G; Percoco G; Bolognese L; Vassanelli C; Colangelo S; de Cesare N; Rodriguez AE; Ferrario M; Moreno R; Piva T; Sheiban I; Pasquetto G; Prati F; Nazzaro MS; Parrinello G; Ferrari R;
JAMA; 2008 Apr; 299(15):1788-99. PubMed ID: 18375998
[TBL] [Abstract][Full Text] [Related]
49. European registry on patients with ST-elevation myocardial infarction transferred for mechanical reperfusion with a special focus on early administration of abciximab -- EUROTRANSFER Registry.
Dudek D; Siudak Z; Janzon M; Birkemeyer R; Aldama-Lopez G; Lettieri C; Janus B; Wisniewski A; Berti S; Olivari Z; Rakowski T; Partyka L; Goedicke J; Zmudka K;
Am Heart J; 2008 Dec; 156(6):1147-54. PubMed ID: 19033011
[TBL] [Abstract][Full Text] [Related]
50. One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial.
Ndrepepa G; Kastrati A; Mehilli J; Neumann FJ; ten Berg J; Bruskina O; Dotzer F; Seyfarth M; Pache J; Dirschinger J; Berger PB; Schömig A
Eur Heart J; 2008 Feb; 29(4):455-61. PubMed ID: 18158289
[TBL] [Abstract][Full Text] [Related]
51. Usefulness of local delivery of thrombolytics before thrombectomy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention (the delivery of thrombolytics before thrombectomy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention [DISSOLUTION] randomized trial).
Greco C; Pelliccia F; Tanzilli G; Tinti MD; Salenzi P; Cicerchia C; Schiariti M; Franzoni F; Speziale G; Gallo P; Gaudio C
Am J Cardiol; 2013 Sep; 112(5):630-5. PubMed ID: 23711809
[TBL] [Abstract][Full Text] [Related]
52. Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in patients with acute myocardial infarction: design and rationale for the MULTI-STRATEGY trial.
Valgimigli M; Bolognese L; Anselmi M; Campo G; Rodriguez AE; de Cesare N; Cohen DJ; Sheiban I; Colangelo S; Pasquetto G; Hamon M; Vranckx P; Ferrario M; Prati F; Agostoni P; Malagutti P; Arcozzi C; Parrinello G; Vassanelli C; Ferrari R; Percoco G
Am Heart J; 2007 Jul; 154(1):39-45. PubMed ID: 17584549
[TBL] [Abstract][Full Text] [Related]
53. Impact of early abciximab administration on infarct size in patients with ST-elevation myocardial infarction.
Petronio AS; De Carlo M; Strata E; Gistri R; Palmieri C; Aquaro G; Borelli G; Vaghetti M; Delle Donne M; Lombardi M; Berti S
Int J Cardiol; 2012 Mar; 155(2):230-5. PubMed ID: 21035211
[TBL] [Abstract][Full Text] [Related]
54. Comparison between fixed-dose, intracoronary bolus-only versus standard weight-adjusted dose, intravenous bolus and infusion administration of abciximab in patients undergoing primary percutaneous coronary intervention.
Lee CH; Ngo HM; Sewianto A; Nguyen TH; Lee J; Teo SG; Low AF; Tan HC
Int J Cardiol; 2010 Nov; 145(2):355-357. PubMed ID: 20227778
[TBL] [Abstract][Full Text] [Related]
55. Angiographic evaluation of the effect of intracoronary abciximab administration in patients undergoing urgent PCI.
Romagnoli E; Burzotta F; Trani C; Mazzari MA; Biondi-Zoccai GG; De Vita M; Giannico F; Niccoli G; Prati F; Rebuzzi AG; Mongiardo R; Crea F
Int J Cardiol; 2005 Dec; 105(3):250-5. PubMed ID: 16274764
[TBL] [Abstract][Full Text] [Related]
56. Early abciximab administration before transfer for primary percutaneous coronary interventions for ST-elevation myocardial infarction reduces 1-year mortality in patients with high-risk profile. Results from EUROTRANSFER registry.
Rakowski T; Siudak Z; Dziewierz A; Birkemeyer R; Legutko J; Mielecki W; Depukat R; Janzon M; Stefaniak J; Zmudka K; Dubiel JS; Partyka L; Dudek D
Am Heart J; 2009 Oct; 158(4):569-75. PubMed ID: 19781416
[TBL] [Abstract][Full Text] [Related]
57. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial.
Kim JS; Kim J; Choi D; Lee CJ; Lee SH; Ko YG; Hong MK; Kim BK; Oh SJ; Jeon DW; Yang JY; Cho JR; Lee NH; Cho YH; Cho DK; Jang Y
JACC Cardiovasc Interv; 2010 Mar; 3(3):332-9. PubMed ID: 20298994
[TBL] [Abstract][Full Text] [Related]
58. Early abciximab administration before primary percutaneous coronary intervention improves clinical outcome in diabetic patients with ST-segment elevation myocardial infarction (EUROTRANSFER Registry).
Dziewierz A; Mielecki W; Siudak Z; Rakowski T; Janzon M; Birkemeyer R; Zasada W; Dubiel JS; Dudek D
Atherosclerosis; 2012 Jul; 223(1):212-8. PubMed ID: 22658254
[TBL] [Abstract][Full Text] [Related]
59. Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial).
Maioli M; Bellandi F; Leoncini M; Toso A; Dabizzi RP
J Am Coll Cardiol; 2007 Apr; 49(14):1517-24. PubMed ID: 17418289
[TBL] [Abstract][Full Text] [Related]
60. ST-segment analysis to predict infarct size and functional outcome in acute myocardial infarction treated with primary coronary intervention and adjunctive abciximab therapy.
Sciagrà R; Parodi G; Migliorini A; Valenti R; Antoniucci D; Sotgia B; Pupi A
Am J Cardiol; 2006 Jan; 97(1):48-54. PubMed ID: 16377283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
